ArticleThe Lancet regional health. Western Pacific2024

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic

Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.